Escitalopram
- CAS No.
- 128196-01-0
- Chemical Name:
- Escitalopram
- Synonyms
- Seroplex;Escitalopram;(+)-Citalopram;Escitalopram CRS;EscitalopraM Oxalate INN;Escitalopram Impurity 31;(S)-(+)-CITALOPRAM OXALATE;(+)-(S)-Citalopram Oxalate;(+)-(S)-Citalopram-d4 Oxalate;Escitalopram oxalate impurity III
- CBNumber:
- CB2712918
- Molecular Formula:
- C20H21FN2O
- Molecular Weight:
- 324.39
- MDL Number:
- MFCD09817397
- MOL File:
- 128196-01-0.mol
- MSDS File:
- SDS
- TDS File:
- TDS
| alpha | D +12.33° (c = 1 in methanol) |
|---|---|
| Boiling point | 428.3±45.0 °C(Predicted) |
| Density | 1.18±0.1 g/cm3(Predicted) |
| storage temp. | 2-8°C |
| solubility | Soluble in DMSO |
| form | Powder |
| pka | 9.57±0.28(Predicted) |
| color | Off-white to light yellow |
| CAS DataBase Reference | 128196-01-0(CAS DataBase Reference) |
| FDA UNII | 4O4S742ANY |
| NCI Dictionary of Cancer Terms | escitalopram |
| ATC code | N06AB10 |
SAFETY
Risk and Safety Statements
| Symbol(GHS) |  GHS07 |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Signal word | Warning | |||||||||
| Hazard statements | H317-H302 | |||||||||
| Precautionary statements | P261-P272-P280-P302+P352-P333+P313-P321-P363-P501-P264-P270-P301+P312-P330-P501 | |||||||||
| Hazardous Substances Data | 128196-01-0(Hazardous Substances Data) | |||||||||
| REACH Registrations | Active | |||||||||
| NFPA 704 |
|
Escitalopram price More Price(47)
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| Cayman Chemical | 22405 | Escitalopram ≥98% | 128196-01-0 | 5mg | $50 | 2026-04-30 | Buy |
| Cayman Chemical | 22405 | Escitalopram ≥98% | 128196-01-0 | 10mg | $90 | 2026-04-30 | Buy |
| Cayman Chemical | 22405 | Escitalopram ≥98% | 128196-01-0 | 25mg | $206 | 2026-04-30 | Buy |
| Cayman Chemical | 22405 | Escitalopram ≥98% | 128196-01-0 | 50mg | $363 | 2026-04-30 | Buy |
| Biosynth | FE102240 | Escitalopram | 128196-01-0 | 25mg | $189 | 2026-06-04 | Buy |
Escitalopram Chemical Properties,Uses,Production
History
Escitalopram (lexapro)was discovered by cooperation between Lundbeck and Forest Laboratories. Its development was initiated in 1997, and the resulting new drug application was submitted to the US FDA in March 2001. The short time (3.5 years) it took to develop escitalopram can be attributed to the previous experience of Lundbeck and Forest with citalopram, which has similar pharmacology. The FDA issued the approval of escitalopram for major depression in August 2002 and for generalized anxiety disorder in December 2003. On May 23 2006, the FDA approved a generic version of escitalopram by Teva. However, on July 14 of that year, the U.S. District Court of Delaware decided in favor of Lundbeck regarding the patent infringement dispute and ruled the patent on escitalopram valid.
Uses
antidepressive;selective serotonin reuptake inhibitor
Uses
(S)-Citalopram is an inhibitor of serotonin (5-HT) uptake. Antidepressant.
Definition
ChEBI: A 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile that has S-configuration at the chiral centre. It is the active enantiomer of citalopram.
Application
Escitalopram is a first-line, highly selective serotonin reuptake inhibitor (SSRI) used clinically to treat major depressive disorder, generalized anxiety disorder, panic disorder, and social anxiety disorder in adults and adolescents aged 12 and older; it also serves as a key active pharmaceutical ingredient (API) for the manufacture of formulations such as escitalopram oxalate tablets and oral solutions. In scientific research, it is frequently employed as a specific tool compound for in vitro screening targeting the serotonin transporter, mechanistic studies using animal models of depression and anxiety, and comparative drug analysis.
Biological Activity
escitalopram （lexapro，cipralex）is a selective inihibitor of serotonin(5-ht) reuptake (ssri) with a ki value of 6.6nm for [3h]-5-ht uptake [1].escitalopram is the s-(+)-enantiomer of citalopram and has the inhibition of [3h]-5-ht uptake and [125i]-rti-55 binding in cos-1 cells expressing the human serotonin transporter (5-htt) with ki values of 6.6±1.4nm and 3.9±2.2nm, respectively. in addition, escitalopram has been reported to inhibit the accumulation of 3h-labelled monoamines into rat brain synaptosomes in vitro with ic50 values of 2.1±0.75nm, 2500±202nm and 40000±15500nm for [3h]-5-ht, [3h]-i-na and [3h]-da, respectively. apart from these, escitalopram has shown the in vitro affinity for rat histamine h1 receptors and the rat sigma σ1 site with ki values of 1500±780nm and 100±71nm, respectively [1].
Mechanism of action
Escitalopram is the S-enantiomer of citalopram that binds with high affinity and selectivity to the human SERT equivalent to (±)-citalopram. It has been reported that nearly all the activity resides in the S-enantiomer and that R-citalopram actually counteracts the action of the S-enantiomer. Studies show that escitalopram exhibits twice the activity of citalopram and is at least 27 times more potent than the R-enantiomer. The R-enantiomer inhibits the S-enantiomer at the transporter. Escitalopram's mechanism of action is common to the SSRIs.
Pharmacokinetics
The pharmacokinetics for escitalopram does not exhibit stereoisomer selectivity and, therefore, is similar to that for citalopram. Likewise, it exhibits linear pharmacokinetics so that plasma levels increase proportionately and predictably with increased doses, and its half-life of 27 to 32 hours is consistent with once-daily dosing. It also has been found that R-citalopram is cleared more slowly than the S-enantiomer. Therefore, when the drug is used as a racemic mixture (citalopram), the inactive isomer predominates at steady state. This is an added incentive for use of the enantiomerically pure escitalopram. Escitalopram has negligible effects on CYP isoforms, suggesting a low potential for drug–drug interactions. Escitalopram is indicated for patients with major depressive disorder, generalized anxiety disorder, panic disorder, and social anxiety disorder.
Clinical Use
SSRI antidepressant:
Depressive illness
Panic and social anxiety disorder
Drug interactions
Potentially hazardous interactions with other drugsAnalgesics: increased risk of bleeding with aspirin and NSAIDs; risk of CNS toxicity increased with tramadol.Anti-arrhythmics: increased risk of ventricular arrhythmias with amiodarone, disopyramide and dronedarone - avoid.Antibacterials: increased risk of ventricular arrhythmias with IV erythromycin, moxifloxacin, pentamidine and telithromycin.Anticoagulants: effect of coumarins possibly enhanced; possibly increased risk of bleeding with dabigatran.Antidepressants: avoid concomitant use with MAOI, increased risk of toxicity; increased risk of CNS toxicity with moclobemide - avoid concomitant use; avoid concomitant use with St John’s wort; possibly enhanced serotonergic effects with dapoxetine and duloxetine; can increase concentration of tricyclics; increased agitation and nausea with tryptophan; increased risk of CNS toxicity with rasagiline; possible increased risk of convulsions with vortioxetineAntiepileptics: convulsive threshold lowered.Antihistamines: increased risk of ventricular arrhythmias with mizolastine - avoid.Antimalarials: avoid concomitant use with artemether/lumefantrine and piperaquine with artenimol; possible increased risk of ventricular arrhythmias with chloroquine and quinine.Antipsychotics: possibly increased risk of ventricular arrhythmias with haloperidol, phenothiazines and pimozide - avoid.Antivirals: concentration possibly increased by ritonavir.Beta-blockers: increased risk of ventricular arrhythmias with sotalol - avoid.Dopaminergics: avoid with selegiline; increased risk of CNS toxicity with rasagiline.5HT1 agonist: increased risk of CNS toxicity with sumatriptan; possibly increased risk of serotonergic effects with naratriptan.Linezolid: use with care, possibly increased risk of side effects.Lithium: increased risk of CNS effectsMethylthioninium: risk of CNS toxicity - avoid if possible.
Metabolism
Escitalopram is metabolised in the liver to the demethylated and didemethylated metabolites. Both of these are pharmacologically active. Alternatively, the nitrogen may be oxidised to form the N-oxide metabolite. Both parent substance and metabolites are partly excreted as glucuronides. After multiple dosing the mean concentrations of the demethyl and didemethyl metabolites are usually 28-31% and <5%, respectively, of the escitalopram concentration. Biotransformation of escitalopram to the demethylated metabolite is mediated primarily by CYP2C19. Some contribution by the enzymes CYP3A4 and CYP2D6 is possible. The major metabolites have a significantly longer half-life than the parent drug.Escitalopram and major metabolites are assumed to be eliminated by both hepatic and renal routes, with the major part of the dose excreted as metabolites in the urine.
References
[1] sánchez c1, bergqvist pb, brennum lt, gupta s, hogg s, larsen a, wiborg o. escitalopram, the s-(+)-enantiomer of citalopram, is a selective serotonin reuptake inhibitor with potent effects in animal models predictive of antidepressant and anxiolytic activities. psychopharmacology (berl). 2003 jun;167(4):353-62. epub 2003 apr 26.
Escitalopram Preparation Products And Raw materials
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| Pure Chemistry Scientific Inc. | 001-857-928-2050 or 1-888-588-9418 | sales@chemreagents.com | United States | 10174 | 62 |
| LGM Pharma | 1-(800)-881-8210 | inquiries@lgmpharma.com | United States | 2110 | 70 |
| S.Z. PhyStandard Bio-Tech. Co., Ltd. | 0755-83725681-603 | China | 4484 | 50 | |
| Beijing HuaMeiHuLiBiological Chemical | 010-56205725 | waley188@sohu.com | China | 12323 | 58 |
| Nanjing Sunlida Biological Technology Co., Ltd. | 025-57798810 18652991625 | sales@sunlidabio.com | China | 3223 | 55 |
| Taizhou Tongxin Bio-Tech Co., Ltd | 0523-86818997 18652728585 | sales@allyrise.com | China | 2986 | 60 |
| Eastbang Pharmaceuticals Technology Co., Ltd. | +86 (20) 28996708,29078958,28139708,29076128,28133708,28139728,28139738,28133718,021-31663278,021-31663578,021-60538387 | China | 454 | 58 | |
| Quality Control Solutions Ltd. | 0755-66853366 13670046396 | orders@qcsrm.com | China | 18188 | 56 |
| Finetech Industry Limited | 027-87465837 19945049750 | sales@finetechnology-ind.com | China | 9331 | 58 |
| Shanghai Macklin Biochemical Co.,Ltd. | 15221275939 15221275939 | shenlinxing@macklin.cn | China | 15775 | 55 |
View Lastest Price from Escitalopram manufacturers
| Image | Update time | Product | Price | Min. Order | Purity | Supply Ability | Manufacturer | |
|---|---|---|---|---|---|---|---|---|
 |
2026-09-12 | Escitalopram
128196-01-0
|
0.99 | RongNa Biotechnology Co.,Ltd | ||||
 |
2026-08-18 | Escitalopram
128196-01-0
|
$40.00-113.00 | 99.88% | 10g | TargetMol Chemicals Inc. | ||
 |
2026-08-18 | Escitalopram
128196-01-0
|
$40.00-113.00 | 99.88% | 10g | TargetMol Chemicals Inc. |
-
- Escitalopram
128196-01-0
- 0.99
- RongNa Biotechnology Co.,Ltd
-
- Escitalopram
128196-01-0
- $40.00-113.00
- 99.88%
- TargetMol Chemicals Inc.
-
- Escitalopram
128196-01-0
- $40.00-113.00
- 99.88%
- TargetMol Chemicals Inc.
